探索SADI-S背后的分子机制 通过肝脏转录和蛋白质组学分析改善2型糖尿病大鼠的葡萄糖代谢
Lun Wang1, Zhengfu Chen2, Subo Ma2
1Department of Gastrointestinal Surgery, Affiliated Hospital of Zunyi Medical University, Zunyi 563000,China.
Journal of proteome research
|November 5, 2024
概括
单次解肠道十二节-节绕道与袖子胃切除术 (SADI-S) 手术改善了2型糖尿病 (T2DM) 鼠的葡萄糖代谢. 这项研究确定了肝脏中涉及SADI-SS的关键分子通路.
科学领域:
- 代谢手术是一种代谢手术.
- 分子生物学分子生物学
- 糖尿病研究研究 糖尿病研究
背景情况:
- 2型糖尿病 (T2DM) 是一个全球性的健康问题.
- 代谢手术,包括SADI-S,在T2DM管理中显示出前景.
- 在T2DM中SADI-S疗效的确切分子机制尚不清楚.
研究的目的:
- 研究SADI-S在改善T2DM中的分子机制.
- 在SADI-S.之后,在肝脏中识别差异表达的基因和蛋白质.
- 使用并行反应监测 (PRM) 验证蛋白质组发现.
主要方法:
- T2DM大鼠模型接受了SADI-S或假手术.
- 8周后肝脏组织的转录和蛋白质分析.
- 选择差异表达蛋白质的PRM验证.
主要成果:
- 在T2DM大鼠中,SADI-S显著改善了葡萄糖代谢.
- 120个基因/蛋白质在mRNA和蛋白质水平上显示出一致的表达变化.
- 上调的途径包括pyruvate代谢,胰岛素信号传递,糖解/葡萄糖生成,葡萄糖信号传递和AMPK信号传递.
- 降低调节的基因/蛋白质在pyruvate代谢途径中得到丰富.
- PRM证实了蛋白质组学数据的准确性和一致性.
结论:
- 在T2DM中,SADI-S有效地改善了葡萄糖代谢.
- 关键代谢途径的持续分子变化表明T2DM改善的机制.
- 这项研究为SADI-S治疗效果提供了可靠的分子洞察力.
相关概念视频
Diabetes Mellitus: Type 2 and Gestational
2.2K
Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
2.2K
Glucose Transporters
22.5K
Glucose transporters facilitate the transport of glucose across the cell membrane. In addition to glucose, some glucose transporters can also aid the movement of other hexoses such as fructose, mannose, and galactose.
Facilitated diffusion-glucose transporters (GLUTs) are encoded by the solute-linked carrier (SLC) family 2, subfamily A gene family, or SLC2A. The 14 GLUT protein members are distributed into three classes:
Facilitated diffusion-glucose transporters (GLUTs) are encoded by the solute-linked carrier (SLC) family 2, subfamily A gene family, or SLC2A. The 14 GLUT protein members are distributed into three classes:
22.5K
Oral Hypoglycemic Agents: Biguanides and Glitazones
175
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
175
Glucagon-like Receptor Agonists
300
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
300
Hormones Regulating Blood Glucose
3.1K
Insulin is released by beta cells of the pancreas when blood glucose levels are high. It facilitates glucose absorption and utilization in insulin-dependent cells with insulin receptors on their plasma membranes. Insulin promotes glucose uptake by increasing the number of glucose transport proteins in the cell membrane, allowing glucose to enter the cell. As a result, glucose utilization and ATP production are enhanced.
In addition to accelerating glucose uptake and utilization, insulin has...
In addition to accelerating glucose uptake and utilization, insulin has...
3.1K
Oral Hypoglycemic Agents: Sulfonylureas
192
Sulfonylureas are oral hypoglycemic agents utilized in treating type 2 diabetes. They are characterized by their unique sulfonylurea chemical structure. The family of sulfonylureas is divided into generations. First-generation sulfonylureas, including tolbutamide (Orinase), chlorpropamide (Diabinese), and tolazamide (Tolinase), trigger insulin release from pancreatic β cells and enhance peripheral tissues' insulin sensitivity. The second-generation members, such as glipizide...
192


